Protalex Announces PRTX-100 Phase I Data Published in The Journal of Clinical Pharmacology SUMMIT, N.J.--(BUSINESS WIRE)--Protalex, Inc. (OTCBB: PRTX), a clinical-stage biopharmaceutical company, today announced publication of the Company’s Phase 1 study with PRTX-100 in healthy volunteers. This article entitled, "Safety, Pharmacokinetic, Immunogenicity, and Pharmacodynamic Responses in Healthy Volunteers Following a Single Intravenous Injection of Purified Staphylococcal Protein A ...
Aug. 15, 2013 - Business Wire